

In the United States Patent and Trademark Office

Serial Number: July 2, 2003
Appn. Filed: July 2, 2003
Applicant(s): DALLAS L CLOUATRE
Appn. Title: (-)-Hydroxyacetic Acid for Controlling Inflammation
Examiner/GAU: _____
Mailed: July 2, 2003
At: Santa Monica, CA

Information Disclosure Statement

Assistant Commissioner for Patents
Washington, District of Columbia 20231

Sir:

Attached is a completed Form PTO-1449 and copies of the pertinent parts of the references cited thereon. Following are comments on any non-English-language references pursuant to Rule 98:

Very respectfully,

Applicant(s): Dallas L Clouatre

Enc.: PTO-1449 & References

c/o: DALLAS L CLOUATRE
1247 LINCOLN BLVD #112
SANTA MONICA, CA 90401

Telephone: 310 / 656 - 0474

Certificate of Mailing

Express

I certify that this correspondence will be deposited with the United States Postal Service as first class mail with proper postage affixed in an envelope addressed to: "Assistant Commissioner for Patents, Washington, DC 20231" on the date below.

Date: 2003 July 2

LIST OF PRIOR ART CITED BY APPLICANT**Sheet 2 of 3****Dallas L. Clouatre****(-)-HYDROXYCITRIC ACID FOR CONTROLLING INFLAMMATION**

July 2, 2003

OTHER PRIOR ART

Bruunsgaard H, et al. Long-term combined supplementations with alpha-tocopherol and vitamin C have no detectable anti-inflammatory effects in healthy men. *J Nutr.* 2003 Apr;133(4):1170-3.

Cloez-Tayarani I, et al. Differential effect of serotonin on cytokine production in lipopolysaccharide-stimulated human peripheral blood mononuclear cells: involvement of 5-hydroxytryptamine(2A) receptors. *Int Immunol.* 2003 Feb;15(2):233-40.

Festa A, et al. Chronic subclinical inflammation as part of the insulin resistance syndrome: the Insulin Resistance Atherosclerosis Study (IRAS). *Circulation.* 2000 Jul 4;102(1):42-7.

Harbuz MS, et al. Alteration of central serotonin modifies onset and severity of adjuvant-induced arthritis in the rat. *Br J Rheumatol.* 1998 Oct;37(10):1077-83.

Koenig W. Inflammation and coronary heart disease: an overview. *Cardiol Rev.* 2001 Jan-Feb;9(1):31-5.

McCarty MF. Promotion of hepatic lipid oxidation and gluconeogenesis as a strategy for appetite control. *Medical Hypotheses* 1994;42:215-225.

Ohia SE, et al. Safety and mechanism of appetite suppression by a novel hydroxycitric acid extract (HCA-SX). *Mol Cell Biochem.* 2002 Sep;238(1-2):89-103.

Pichler R, et al. Pro-inflammatory role of serotonin and interleukin-6 in arthritis and spondyloarthropathies--measurement of disease activity by bone scan and effect of steroids. *Scand J Rheumatol.* 2002;31(1):41-3.

Staels B, et al. Activation of human aortic smooth-muscle cells is inhibited by PPAR α but not by PPAR γ activators. *Nature.* 1998 Jun 25;393(6687):790-3.

Sullivan AC, Triscari J. Metabolic regulation as a control for lipid disorders. I. Influence of (-)-hydroxycitrate on experimentally induced obesity in the rodent. *American Journal of Clinical Nutrition* 1977;30:767-775.

LIST OF PRIOR ART CITED BY APPLICANT

Sheet 3 of 3

Dallas L. Clouatre

(-)-HYDROXYCITRIC ACID FOR CONTROLLING INFLAMMATION

July 2, 2003

Sullivan, Ann C. and Joseph Triscari. Possible interrelationship between metabolite flux and appetite. In D. Novin, W. Wyriwicka and G. Bray, eds., Hunger: Basic Mechanisms and Clinical Implications (New York: Raven Press, 1976) 115-125.

Sullivan AC, Gruen RK. Mechanisms of appetite modulation by drugs. Federation Proceedings 1985;44,1:139-144.

Thomas SR, et al. Dietary cosupplementation with vitamin E and coenzyme Q(10) inhibits atherosclerosis in apolipoprotein E gene knockout mice. Arterioscler Thromb Vasc Biol. 2001 Apr;21(4):585-93.

FORM PTO-1449 (Substitution)		ATTY. DOCKET NO.	SERIAL NO.
LIST OF PRIOR ART CITED BY APPLICANT (Use several sheets if necessary)		APPLICANT	
		CLOUATRE	
		FILING DATE	GROUP
		July 2, 2003	

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
AA	20030119913	06/2003	Ohia, et al.	514	574	
AB	20020187943	12/2002	Majeed, et al.	514	27	
AC	6,476,071	11/2002	Clouatre, et al.	514	557	
AD	6,221,901	04/2001	Shrivastava, et al.	514	458	
AE	5,914,326	06/1999	McCarty, et al.	514	188	
AF	5,783,603	07/1998	Majeed, et al.	514	574	
AG	5,656,314	08/1997	Moffett, et al.	426	271	
AH	3,993,668	11/1976	Guthrie, et al.	260	343.6	
AI	3,919,254	11/1975	Guthrie, et al.	260	343.6	
AJ	3,767,678	10/1973	Guthrie, et al.	260	343.6	
AK	3,764,692	10/1973	Lowenstein	424	279	

FOREIGN PATENT DOCUMENTS

AL	WO 02/078616	10/2002	Ohia, et al.			
AM	WO 02/14477	02/2002	Majeed, et al.			
AN						
AO						
AP						

OTHER PRIOR ART (Including Author, Title, Date, Page(s), Etc.)

AR	SEE ATTACHED SHEETS					
AS						
AT						

EXAMINER	DATE CONSIDERED
----------	-----------------

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.